New drug approval: Pembrolizumab in association with chemotherapy as first line treatment for advanced/metastatic oesophageal carcinomas or HERnegative gastroesophageal adenocarcinoma, expressing PD-L1 with a CPS≥10

xlomafota13 shared this article with you from Inoreader New drug approval: Pembrolizumab in association with chemotherapy as first line treatment for advanced/metastatic oesophageal carcinomas or HERnegative gastroesophageal adenocarcinoma, expressing PD-L1 with a CPS≥10 Via Association française pour l'étude du cancer Bull Cancer. 2022 Jan 5:S0007-4551(21)00575-0. doi: 10.1016/j.bulcan.2021.09.021. Online ahead of print. NO ABSTRACT PMID:34998526 | DOI:10.1016/j.bulcan.2021.09.021 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.